Gregory Cowan Net Worth

Gregory Cowan biography

Gregory L. Cowan serves as Independent Director of the Company. Mr. Cowan previously served for one year as the Executive Vice President and Chief Financial Officer of Avantor, Inc. Mr. Cowan has also served for eight years as the Senior Vice President and Chief Financial Officer and five years as Corporate Controller of VWR Corporation, which was acquired by Avantor, Inc. in 2017. Prior to joining VWR Corporation, Mr. Cowan spent approximately five years at CDI Corporation, a professional services company, in various senior financial positions, most recently as Senior Vice President and Chief Accounting Officer. Prior to CDI Corporation, he was Vice President of Internal Audit at Crown Holdings, Inc. (formerly Crown Cork and Seal Company Inc.) for approximately eight years and a senior manager at PricewaterhouseCoopers LLC, where he served in various audit and consulting capacities for eleven years. Mr. Cowan also previously served as a director of Emtec, Inc., including as the chairman of its audit committee and member of its compensation committee. He graduated from Rutgers University with a degree in accounting and finance. Mr. Cowan is being nominated to serve on our board of directors because his financial acumen, corporate governance expertise and experience growing businesses.

What is the salary of Gregory Cowan?

As the Independent Director of Osmotica Pharmaceuticals Plc, the total compensation of Gregory Cowan at Osmotica Pharmaceuticals Plc is $402,911. There are 10 executives at Osmotica Pharmaceuticals Plc getting paid more, with Brian Markison having the highest compensation of $4,338,620.

How old is Gregory Cowan?

Gregory Cowan is 66, he's been the Independent Director of Osmotica Pharmaceuticals Plc since 2019. There are 1 older and 15 younger executives at Osmotica Pharmaceuticals Plc. The oldest executive at Osmotica Pharmaceuticals Plc is Fred Weiss, 78, who is the Independent Director.

What's Gregory Cowan's mailing address?

Gregory's mailing address filed with the SEC is C/O OSMOTICA PHARMACEUTICALS PLC, 400 CROSSING BOULEVARD, BRIDGEWATER, NJ, 08807.

Insiders trading at Osmotica Pharmaceuticals Plc

Over the last 6 years, insiders at Osmotica Pharmaceuticals Plc have traded over $0 worth of Osmotica Pharmaceuticals Plc stock and bought 6,343,800 units worth $31,350,366 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman y Ltd Orbit Co Invest A 1 Llc.... On average, Osmotica Pharmaceuticals Plc executives and independent directors trade stock every 117 days with the average trade being worth of $1,173,603. The most recent stock trade was executed by James Schaub on 16 December 2021, trading 93,800 units of OSMT stock currently worth $100,366.

What does Osmotica Pharmaceuticals Plc do?

Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.

Osmotica Pharmaceuticals Plc executives and stock owners

Osmotica Pharmaceuticals Plc executives and other stock owners filed with the SEC include:

• Brian Markison,
  Chairman of the Board, Chief Executive Officer
• Christopher Klein,
  General Counsel, Secretary
• Tina deVries,
  Executive Vice President - Research & Development
• James Schaub,
  Chief Operating Officer, Executive Vice President
• Brian A. Markison,
  Chairman, Pres & CEO
• Christopher A. Klein,
  Gen. Counsel & Sec.
• James D. Schaub,
  Exec. VP & COO
• Dr. Tina Marie deVries,
  Exec. VP of R&D
• Andrew Einhorn,
  Chief Financial Officer
• Fred Weiss,
  Independent Director
• Gregory Cowan,
  Independent Director
• David Burgstahler,
  Director
• Sriram Venkataraman,
  Director
• Juan Vergez,
  Director
• Michael DeBiasi,
  Independent Director
• Lisa Wilson,
  IR Contact Officer
• Joachim Benes,
  Director
• Andrew J. Einhorn CPA,
  Chief Financial Officer
• Jarret Miller,
  Exec. VP of HR
• Sergio Alegre,
  VP of Global Compliance
• Capital Partners Iii Gp, L....,
  
• Ltd Orbit Co Invest A 1 Llc...,
  
• Foundation Harsaul,
  10% owner
• Capital Partners Iii Gp, L....,